NASDAQ:BGNE

BeiGene News Headlines

$305.54
-2.27 (-0.74 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$302.04
Now: $305.54▼
$308.14
50-Day Range
$289.22
MA: $321.65▼
$355.96
52-Week Range
$136.48
Now: $305.54▼
$388.97
Volume168,151 shs
Average Volume309,021 shs
Market Capitalization$28.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.91

Headlines

BeiGene (NASDAQ BGNE) News Headlines Today

SourceHeadline
BRIEF-BeiGene Presents Interim Analysis Results Of Rationale 303 Trial Of Tislelizumab In Second- Or Third-Line Non-Small Cell Lung Cancer At Aacr Annual MeetingBRIEF-BeiGene Presents Interim Analysis Results Of Rationale 303 Trial Of Tislelizumab In Second- Or Third-Line Non-Small Cell Lung Cancer At Aacr Annual Meeting
msn.com - April 13 at 12:08 PM
BeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination - NasdaqBeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination - Nasdaq
nasdaq.com - April 12 at 10:44 PM
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021 - Business WireBeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021 - Business Wire
businesswire.com - April 12 at 5:43 PM
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
finance.yahoo.com - April 12 at 5:43 PM
BeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab CombinationBeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination
finance.yahoo.com - April 12 at 12:43 PM
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 - Business WireBeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 - Business Wire
businesswire.com - April 11 at 7:25 PM
BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints - StreetInsider.comBeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints - StreetInsider.com
streetinsider.com - April 9 at 5:51 AM
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress - Yahoo FinanceBeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress - Yahoo Finance
finance.yahoo.com - April 8 at 7:32 AM
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s MacroglobulinemiaBeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
finance.yahoo.com - April 8 at 7:32 AM
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary DistressBeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
finance.yahoo.com - April 8 at 7:32 AM
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, ChinaBeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China
finance.yahoo.com - April 7 at 7:52 PM
BeiGene (NASDAQ:BGNE) Trading Down 4.2% Following Insider SellingBeiGene (NASDAQ:BGNE) Trading Down 4.2% Following Insider Selling
americanbankingnews.com - April 1 at 12:22 PM
BeiGene, Ltd. (NASDAQ:BGNE) CMO Sells $486,000.00 in StockBeiGene, Ltd. (NASDAQ:BGNE) CMO Sells $486,000.00 in Stock
americanbankingnews.com - March 31 at 7:48 PM
Stocks Showing Improving Market Leadership: Beigene Earns 82 RS Rating - Investors Business DailyStocks Showing Improving Market Leadership: Beigene Earns 82 RS Rating - Investor's Business Daily
investors.com - March 30 at 3:37 PM
BeiGene (BGNE) Names Julia Wang as New CFO - StreetInsider.comBeiGene (BGNE) Names Julia Wang as New CFO - StreetInsider.com
streetinsider.com - March 30 at 3:37 PM
BeiGene names Julia Wang CFO - Seeking AlphaBeiGene names Julia Wang CFO - Seeking Alpha
seekingalpha.com - March 30 at 3:37 PM
BeiGene Announces New Chief Financial Officer, Julia Wang - Business WireBeiGene Announces New Chief Financial Officer, Julia Wang - Business Wire
businesswire.com - March 30 at 3:37 PM
BeiGene Announces New Chief Financial Officer, Julia WangBeiGene Announces New Chief Financial Officer, Julia Wang
finance.yahoo.com - March 30 at 10:36 AM
Personalis Announces Collaboration with MapKure to Use Personalis NeXT Platform™ for Clinical Trials and Companion Diagnostic Development - Business WirePersonalis Announces Collaboration with MapKure to Use Personalis' NeXT Platform™ for Clinical Trials and Companion Diagnostic Development - Business Wire
businesswire.com - March 29 at 8:08 PM
Hutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor Study - BenzingaHutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor Study - Benzinga
benzinga.com - March 25 at 5:20 PM
Chi-Med, BeiGene launches mid-stage combo study in solid tumors - Seeking AlphaChi-Med, BeiGene launches mid-stage combo study in solid tumors - Seeking Alpha
seekingalpha.com - March 24 at 5:52 AM
Beigene Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investors Business DailyBeigene Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
investors.com - March 22 at 1:35 PM
BeiGene (BGNE) Doses First Patient in Phase 1 Trial of BGB-15025 - StreetInsider.comBeiGene (BGNE) Doses First Patient in Phase 1 Trial of BGB-15025 - StreetInsider.com
streetinsider.com - March 11 at 9:23 AM
BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 - Yahoo FinanceBeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 - Yahoo Finance
finance.yahoo.com - March 11 at 12:04 AM
BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 - Business WireBeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 - Business Wire
businesswire.com - March 10 at 7:04 PM
BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021
finance.yahoo.com - March 10 at 7:04 PM
Dosing underway in BeiGenes study of HPK1 inhibitor BGB-15025 - Seeking AlphaDosing underway in BeiGene's study of HPK1 inhibitor BGB-15025 - Seeking Alpha
seekingalpha.com - March 10 at 2:03 PM
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 - Business WireBeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 - Business Wire
businesswire.com - March 10 at 9:02 AM
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025
finance.yahoo.com - March 10 at 9:02 AM
BeiGenes tislelizumab lung cancer sBLA accepted in China - Seeking AlphaBeiGene's tislelizumab lung cancer sBLA accepted in China - Seeking Alpha
seekingalpha.com - March 5 at 5:53 PM
BeiGene (BGNE) Announces Acceptance of sBLA in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer - StreetInsider.comBeiGene (BGNE) Announces Acceptance of sBLA in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer - StreetInsider.com
streetinsider.com - March 5 at 12:52 PM
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer - Business WireBeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer - Business Wire
businesswire.com - March 5 at 12:52 PM
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung CancerBeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer
finance.yahoo.com - March 5 at 12:52 PM
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s MacroglobulinemiaHealth Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
finance.yahoo.com - March 2 at 9:28 AM
BeiGene downgraded by CLSA after 2020 earnings miss - Seeking AlphaBeiGene downgraded by CLSA after 2020 earnings miss - Seeking Alpha
seekingalpha.com - March 1 at 1:36 PM
UPDATE: CLSA Downgrades BeiGene, Ltd. (BGNE) to Underperform (4) - StreetInsider.comUPDATE: CLSA Downgrades BeiGene, Ltd. (BGNE) to Underperform (4) - StreetInsider.com
streetinsider.com - March 1 at 8:35 AM
Can BeiGene Stock Rebound After A 10% Drop? - NasdaqCan BeiGene Stock Rebound After A 10% Drop? - Nasdaq
nasdaq.com - February 28 at 7:17 PM
BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Years Revenue Estimates By 33% - Yahoo Finance AustraliaBeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33% - Yahoo Finance Australia
finance.yahoo.com - February 27 at 8:51 AM
BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Years Revenue Estimates By 33%BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33%
finance.yahoo.com - February 27 at 8:51 AM
BeiGene closes - Seeking AlphaBeiGene closes - Seeking Alpha
seekingalpha.com - February 26 at 5:49 PM
Can BeiGene Stock Rebound After A 10% Drop?Can BeiGene Stock Rebound After A 10% Drop?
forbes.com - February 26 at 12:48 PM
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan - Yahoo FinanceBeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan - Yahoo Finance
finance.yahoo.com - February 26 at 7:48 AM
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and JapanBeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
finance.yahoo.com - February 26 at 7:48 AM
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection - StreetInsider.comAssembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection - StreetInsider.com
streetinsider.com - February 26 at 1:19 AM
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights - StreetInsider.comSpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights - StreetInsider.com
streetinsider.com - February 25 at 10:17 AM
Form 8-K Zymeworks Inc. For: Feb 24 - StreetInsider.comForm 8-K Zymeworks Inc. For: Feb 24 - StreetInsider.com
streetinsider.com - February 25 at 12:54 AM
Leap Therapeutics to Present at Upcoming Virtual Investor Conferences - StreetInsider.comLeap Therapeutics to Present at Upcoming Virtual Investor Conferences - StreetInsider.com
streetinsider.com - February 22 at 7:40 PM
Leap Therapeutics to Present at Upcoming Virtual Investor Conferences - Yahoo FinanceLeap Therapeutics to Present at Upcoming Virtual Investor Conferences - Yahoo Finance
finance.yahoo.com - February 22 at 9:39 AM
BeiGenes US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review - BenzingaBeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review - Benzinga
benzinga.com - February 18 at 7:55 PM
BeiGene, Ltd. (BGNE) PT Raised to $429 at Cowen - StreetInsider.comBeiGene, Ltd. (BGNE) PT Raised to $429 at Cowen - StreetInsider.com
streetinsider.com - February 18 at 9:54 AM
This page was last updated on 4/17/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.